Efrahim SARGIN, SİNEM ÜLGEN, Mehmet Erman OR

İKİNCİ KUŞAK TRİAZOL TÜREVİ ANTİMİKOTİK POSAKONAZOLÜN VETERİNER HEKİMLİK ALANINDA KLİNİK KULLANIMI

Fungal inf eksiyonlar özellikle bağışıklık sistemi baskılanmış hastalarda önemli bir sorundur. Aynı zamanda bilinen antimikotiklerin kullanımı da mantar etkenlerinin bu antimikotik ilaçlara karşı direnç oluşumuna neden olmaktadır. Özellikle inatçı mikozlarda yeni antimikotiklerin kullanımı tedavi aşamasında bu şekilde oluşabilecek engelleri ortadan kaldırmaya yönelik yeni bir çözüm olabilir. Etkisini mantar hücre zarındaki primer sterol olan ergosterolün sentezini inhibe ederek gerçek- leştiren ikinci kuşak bir triazol türevi olan posakonazolün sistemik ve diğer mikotik inf eksiyonlarda tek başına veya diğer antimikotik ajanlarla kombine olarak kullanımı güncel çalışmalarla desteklenmektedir. Bu derlemede veteriner hekimlik prati- ğinde posakonazol kullanımına yönelik bilgi verilmektedir.

Clinical Use of Posaconazole, a Second Generation Triazole in Veterinary Medicine

Fungal inf ections are considerable problems especially in immunosupressed patients. Common use of current classes of antif ungal agents leads to development of drug resistance. Particularly in persistent mycosis, use of new-developed antimyco- tic agents may be a new solution in treatment period. Clinical eff icacy of alone or combined use of posaconazole, which causes an inhibition of the synthesis of the primer sterol, ergosterol, in the cell membrane of f ungal agent, is conf irmed with current studies. In this review, it is aimed to enlighten the clinical use of posaconazole in veterinary practice.

PDF

___

1. Barachetti L, Mortellaro CM, Di Giancamillo M et al. Bilateral orbital and nasal aspergillosis in a cat, Vet Ophthalmol 2009;12(3):176-82. http://dx.doi.org/10.1111/j.1463-5224.2009.00695.x 2. Bueid A, Howard SJ, Moore CB et al. Azole anti- fungal resistance in Aspergillus fumigatus: 2008 and 2009, J Antimicrob Chemother 2010;65(10):2116-8. http://dx.doi.org/10.1093/jac/dkq279 3. Calvo E, Pastor FJ, Rodriguez MM, Mayayo E, Salas V, Guarro J. Murine model of a disseminated infection by the novel fungus Fonsecaea monop- hora and successful treatment with posaconazole, Antimicrob Agents Chemother 2010;54(2):919-23. http://dx.doi.org/10.1128/AAC.01284-09 4. Evans N, Gunew M, Marshal R, Martin P, Barrs V. Focal pulmonary granuloma caused by Cladophialophora bantiana in a domestic short haired cat, Med Mycol 2011;49(2):194-7. http://dx.doi.org/10.3109/13693786.2010.519349 5. Galhardo MCG, De Oliveira RMZ, Do Volle ACF et al. Molecular epidemiology and antifungal sus- ceptibility patterns of Sporothrix schenckii isola- tes from a cat-transmitted epidemic of sporotric- hosis in Rio de Janeiro, Brazil, Med Mycol 2008;46(2):141-51. http://dx.doi.org/10.1080/13693780701742399 6. Herrin KV, Miranda A, Loebenberg D. Posaconazole therapy for systemic coccidioidomycosis in a chimpanzee (Pan troglodytes): a case report, Mycoses 2005;48(6):447-52. http://dx.doi.org/10.1111/j.1439-0507.2005.01155.x 7. Hilton H, Galuppo L, Puchalski SM et al. Successful treatment of invasive pulmonary aspergillosis in a neonatal foal, J Vet Internal Med 2009;23(2):375-8. http://dx.doi.org/10.1111/j.1939-1676.2009.0272.x 8. Howard SJ, Cerar D, Anderson MJ et al. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure, Emerg Inf ect Dis 2009;15(7):1068-76. http://dx.doi.org/10.3201/eid1507.090043 9. Kablan ANM, Or ME, Uysal A. Veteriner pratiğin- de geniş antifungal spektrumlu triazol: vorikona- zol, ANKEM Derg 2009;23(3):149-53. 10. Krockenberger MB, Martin P, Halliday C, Rothwell TLW, Clarke K, Malik R. Localised Microsphaeropsis arundinis infection of the subcutis of a cat, J Feline Med Surg 2010;12(3):231-6. http://dx.doi.org/10.1016/j.jfms.2010.01.006 11. Kluger EK, Della Torre PK, Martin P, Krockenberger MB, Malik R. Concurrent Fusarium chlamydospo- rum and Microsphaeropsis arundinis infections in a cat, J Feline Med Surg 2004;6(4):271-7. http://dx.doi.org/10.1016/j.jfms.2003.08.006 12. Lozano-Chiu M, Arikan S, Paetznick VL, Anaissie EJ, Loebenberg D, Rex JH. Treatment of murine fusariosis with SCH 56592, Antimicrob Agents Chemother 1999;43(3):589-91. 13. Meletiadis J, Meis JF, Mouton JW, Rodriquez- Tudela JL, Donnelly JP,Verweij PE. In vitro activi- ties of new and conventional antifungal agents against clinical Scedosporium isolates, Antimicrob Agents Chemother 2002;46(1):62-8. http://dx.doi.org/10.1128/AAC.46.1.62-68.2002 14. McLellan GJ, Aquino SM, Mason DR, Kinyon JM, Myers RK. Use of posaconazole in the manage- ment of invasive orbital aspergillosis in a cat, J Am Anim Hosp Assoc 2006;42(4):302-7. 15. Odabaşı Z. Antifungal profilaksi, ANKEM Derg 2007;21(Ek 2):216-9. 16. Perea S, Patterson TF. Antifungal resistance in pat- hogenic fungi, Clin Inf ect Dis 2002;35(9):1073-80. http://dx.doi.org/10.1086/344058 17. Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ, Jones RN. In vitro activities of voricona- zole, posaconazole, and four licensed systemic antifungal agents against Candida species infre- quently isolated from blood, J Clin Microbiol 2003;41(1):78-83. http://dx.doi.org/10.1128/JCM.41.1.78-83.2003 18. Richard JL, Debey MC, Chermette R et al. Advances in veterinary mycology, J Med Vet Mycol 1994;32(Suppl 1):169-87. http://dx.doi.org/10.1080/02681219480000811 19. Rochette F, Engelen M, Vanden Bossche H. Antifungal agents of use in animal health-practical applications, J Vet Pharmacol Ther 2003;26(1):31-53. http://dx.doi.org/10.1046/j.1365-2885.2003.00457.x 20. Sabatelli F, Patel R, Mann PA et al. In vitro activi- tes of posaconazole, fluconazole, itraconazole, voriconazole and amphotericin B against a large collection of clinically important molds and yeasts, Antimicrob Agents Chemother 2006;50(6):2009-15. http://dx.doi.org/10.1128/AAC.00163-06 21. Sponsel WE, Graybill JR, Nevarez HL, Dang D. Ocular and systemic posaconazole (SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis, Br J Ophthalmol 2002;86(7):829-30. http://dx.doi.org/10.1136/bjo.86.7.829-a 22. Uchida K, Yokota N, Yamaguchi H. In vitro anti- fungal activity of posaconazole against various pathogenic fungi, Int J Antimicrobial Agents 2001;18(2):167-72. http://dx.doi.org/10.1016/S0924-8579(01)00363-6 23. Walsh TJ, Petraitis V, Petraitiene R et al. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amp- hotericin B, J Inf ect Dis 2003;188(2):305-19. http://dx.doi.org/10.1086/377210 24. Wray JD, Sparkes AH, Johnson EM. Infection of the subcutis of the nose in a cat caused by Mucor species: successful treatment using posaconazole, J Feline Med Surg 2008;10(5):523-7. http://dx.doi.org/10.1016/j.jfms.2008.06.001